# To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004

> **NCT06169059** · PHASE1 · COMPLETED · sponsor: **Jeil Pharmaceutical Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Healthy Adult

## Interventions

- **DRUG:** JLP-2004
- **DRUG:** JC-013

## Key facts

- **NCT ID:** NCT06169059
- **Lead sponsor:** Jeil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-05
- **Primary completion:** 2023-11-08
- **Final completion:** 2023-11-19
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06169059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06169059, "To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06169059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*